In a latest update, oro-mucosal drug delivery player SUDA Pharmaceuticals Ltd (ASX:SUD) notified that the Therapeutic Goods Administration (TGA) review for ZolpiMistTM is expected to be completed by Q4 2020, subject to the TGA feedback.
SUDA added that the TGA is continuing with the review of additional data submitted by the company for ZolpiMistTM, which supports the quality of the product being produced using the new active pharmaceutical ingredient (API) supplier and manufacturer.
The Company will also share this data with its current and future partners to back their regulatory submissions.
SUD is trading with a rise of ~6.5 per cent at $0.049 as at 11:54 AM AEST on 12th May 2020.
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
